ClinicalTrials.gg
Not yet recruitingNCT07247370KET-DUALUpdated Nov 25, 2025

Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)

A Phase 1/2 interventional study of Ketamine and Cognitive Behavioural Therapy in Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) and Comorbidities and Coexisting Conditions, sponsored by South West Sydney Local Health District. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by South West Sydney Local Health District · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing ketamine in Alcoholism — 5 open to participants now, 5 under way, none of them phase 3. Ketamine · Alcoholism.

Planned enrollment
7th of 10
20 · median 32
Started
2025
with 3 others
Phase 1/2
3 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
South West Sydney Local Health District

Among the 10 studies testing ketamine in Alcoholism, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 1/2, and was the 10th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

5 of the 10 studies testing ketamine in Alcoholism are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ketamine in Alcoholism, or all of them as a file.
02

Study summary

To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.

Read the detailed description

New strategies for the treatment of alcohol use disorder (AUD) and co-morbid major depressive disorder (MDD) are urgently required. This population represents a high-risk group that has largely been excluded from addiction-focused trials despite its clinical complexity and poor response to standard interventions.

Recent early phase studies have shown that ketamine-enhanced psychotherapy (KET) can reduce alcohol consumption, enhance motivation and alleviate depressive symptoms. Effects have been shown to be particularly pronounced among participants who also received motivational enhancement therapy, suggesting a synergistic effect between ketamine and psychotherapy.

Emerging evidence suggests that KET may be of promise for AUD, and has demonstrated a good safety profile and potential efficacy in alcohol dependence. However, no trials to date have specifically targeted AUD and co-morbid MDD.

This project will assess the clinical safety, feasibility and preliminary efficacy of KET in individuals with AUD and co-morbid MDD. The investigators hypothesise that KET will be safe and feasible to deliver in this population, and expect to observe preliminary improvements in alcohol consumption, depressive symptoms, and treatment engagement. The KET intervention is also anticipated to be well tolerated with high levels of session attendance and acceptable rates of adverse events.

The trial will utilise an open-label, single-arm, pilot clinical trial design. A sample of 20 individuals will receive 6 weeks of treatment including 6 manualized cognitive-behavioural therapy sessions and 3 dosing sessions with Ketamine administered at 2 week intervals (0.7mg/kg initially up).

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Major Depressive Disorder (MDD)
  • Comorbidities and Coexisting Conditions

Keywords

  • Ketamine-enhanced psychotherapy
  • Open-label
  • Single-arm
  • Ketamine
  • Concurrent Treatment of AUD and comorbid MDD
  • Alcohol Use Disorder (AUD)
  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Moderate to severe AUD according to the 5th Edition (DSM-V) criteria
  2. Presence of current Major Depressive Disorder (MDD), according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) criteria
  3. Expressed motivation to reduce or cease alcohol consumption.
  4. Consumed at least 21 standard drinks per week or 2 HDD per week (≥5 standard drinks/day for men; ≥4 for women) in the month prior to screening
  5. Age 18-70
  6. Adequate cognition and English language skills to give valid consent and complete research interviews
  7. Stable housing
  8. Willingness to give written .
  9. Willingness to comply with study procedures and attend scheduled visits.

Exclusion criteria

Exclusion Criteria:

  1. diagnosis of current or past psychotic disorder, bipolar I disorder, or substance-induced psychosis.
  2. Current acute suicidality, defined as high risk by the Columbia Suicide Severity Rating Scale (C-SSRS) or clinical judgment or attempts in the past 6 months.
  3. DSM-5 diagnosis of current or past moderate-to-severe ketamine or other dissociative drug use disorder.
  4. Use of ketamine (prescribed or non-prescribed) in the previous 4 weeks.
  5. Enrolment in another interventional clinical trial that may interfere with safety, data quality, or trial participation.
  6. Pregnant or breastfeeding, or planning to become pregnant during the course of the study.
  7. Significant uncontrolled medical conditions, including but not limited to:

    • Severe or poorly controlled hypertension (>160/100 mmHg)
    • Severe cardiovascular disease (e.g., heart failure, recent myocardial infarction, dysrhythmia)
    • History of stroke, cerebral trauma, or intracranial mass/haemorrhage
    • Severe hepatic impairment (e.g., MELD ≥10) or end-stage liver disease, bladder or kidney disease
  8. alcohol withdrawal at screening (e.g., CIWA-Ar ≥10, history of delirium tremens).
  9. History of heightened intracranial pressure, seizures, or diagnosed seizure disorder (except childhood febrile seizures).
  10. Known to ketamine or any .
  11. Concurrent use of psychotropic medications (other than stable-dose antidepressants ≥4 weeks).
  12. Active substance use disorder (moderate or severe) other than nicotine or caffeine; stable opioid use disorder permitted if on maintenance therapy (with strict stability criteria).
  13. Inability or unwillingness to comply with study procedures, judged by the principal investigator.
  14. Any clinically significant medical or psychiatric condition that, in the judgment of the Principal Investigator, poses a safety risk or could confound study results or hinder protocol adherence.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ketamine-enhanced therapy (KET): sub-anesthetic ketamine plus structured psychotherapy

    1. x CBT session (Week 1) Dose 1: 1x Sub-anaesthetic subcutaneous dose of racemic ketamine (initially 0.7mg/kg, up to a potential maximum of 1.2mg/kg, at the discretion of the principal investigator and permitted based on tolerability) (Week 2) 2. x CBT sessions (Week 2 - 3) Dose 2: 1x Sub-anaesthetic subcutaneous dose of racemic ketamine (initially 0.7mg/kg, up to a potential maximum of 1.2mg/kg, at the discretion of the principal investigator and permitted based on tolerability (Week 4) 2 x CBT sessions (Week 4 - 5) Dose 3: 1x Sub-anaesthetic subcutaneous dose of racemic ketamine (initially 0.7mg/kg, up to a potential maximum of 1.2mg/kg, at the discretion of the principal investigator and permitted based on tolerability (Week 6) 1x CBT session (Week 6)

    Drug: Ketamine · Behavioral: Cognitive Behavioural Therapy

Interventions

  • Subcutaneous administration of of Ketamine across 3 dosing sessions (at week 2, 4 and 6). Dosing adjustments are permitted based on tolerability, with a minimum dose of 0.7mg/kg and a potential maximum of 1.2 mg/kg, at the discretion of the principal investigator (previous studies have found efficacy at 0.8mg/kg for AUD).

  • BehavioralCognitive Behavioural Therapy

    This study uses a manualized CBT program adapted for ketamine-assisted context. It integrates evidence-based CBT for substance use and depression with principles of psychedelic-assisted therapy, including "set and setting." considerations central to psychedelic-assisted therapy. The therapist manual includes guidance on psychological preparation, intention-setting, integration, and therapeutic framing of ketamine experiences. Participants receive six 90-minute sessions over six weeks, delivered by trained health professionals (e.g., psychologists, mental health nurses, social workers) with specific training in the adapted CBT protocol and psychedelic-assisted therapy. Sessions include: Preparation (Week 1): Review of alcohol use, treatment goals, and ketamine orientation. Integration (Weeks 2, 4, 6): Post-dose processing and linking experience to recovery goals occurring 24-48 hours post dose. Continued CBT (Weeks 3, 5): Coping strategies, goal setting, and relapse prevention.

    Also known as: CBT, Psychotherapy

06

What researchers measure

Primary outcomes

  1. Feasibility will be assessed through recruitment rates, retention to follow-up, session attendance, and treatment adherence.

    Feasibility outcomes will be assessed by the traffic light framework may be applied to guide progression decisions for future trials for each of the following variables: (i) time taken to recruit the sample; (ii) proportion of ineligible participants at (a) pre tele-screening and (b) onsite screening; (iii) number of participants who receive (a) at least two doses of ketamine and (b) at least four CBT sessions; (iv) retention rate over the trial. As this is the first study of its kind in this population and pilot studies are not generalisable to other contexts, these will be assessed and reported descriptively. Results will be synthesised in consideration of the feasibility to progress to larger studies, taking into account the measures described above. Specifically, based on our prior trials of CBT, pharmaco-assisted therapy and complex S9 trials, the following would be an estimation of failure to progress to full trial for each variable and when taken together: (i) \> 24 months; (ii)

    Time frame: 22 weeks

  2. Safety will be assessed through the frequency, severity, and relatedness of adverse events (AEs), including dissociation, affective destabilisation, and vital sign abnormalities.

    Safety outcomes including adverse events (AEs), serious adverse events (SAEs), and vital sign abnormalities, will be summarised descriptively across the study period. Feasibility outcomes (e.g., recruitment and retention rates, session attendance) will be analysed using proportions with corresponding 95% confidence intervals.

    Time frame: 22 weeks

Secondary outcomes

  1. Number of Heavy Drinking Days per week (HDDs) (>5 standard drinks/day for men; >4 for women) and total alcohol consumption.

    This will be measured by the Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 22 weeks

  2. Change in depressive symptoms measured by MADRS and DASS-21.

    MADRS is a clinician-administered rating scale designed to assess the severity of depressive episodes in patients with mood disorders. It is widely used in clinical trials and psychiatric evaluations due to its sensitivity to treatment-related changes. The MADRS will be administered by trained health care professionals. The MADRS total score is calculated by summing the scores of 10 individual items, each rated on a scale from 0 to 6, yielding a total score range of 0 to 60. Higher scores indicate greater severity of depressive symptoms. The 10 items assessed in the MADRS include: Apparent sadness Reported sadness Inner tension Reduced sleep Reduced appetite Concentration difficulties Lassitude/Sluggishness Inability to feel (emotional capacity) Pessimistic thoughts Suicidal thoughts Each item is rated based on clinical judgment following a semi-structured interview, focusing on the past week. Clinically meaningful changes will be reported descriptively, including rates of ≥50%

    Time frame: 22 weeks

  3. Changes in suicidal ideation (weekly monitoring) using the Columbia Suicide Severity Rating Scale (C-SSRS).

    The C-SSRS is a structured clinician-administered instrument with strong predictive validity for suicidal behavior, used in clinical and research settings to assess the presence, severity, and intensity of suicidal ideation and behavior. The C-SSRS is administered by trained clinicians. C-SSRS scoring includes four subscales: ideation severity (items 1-5, scored by the most severe type endorsed); intensity of ideation (sum of five items including frequency, duration, controllability, deterrents, and reasons for ideation; range 2-25; higher number indicates more intense ideation); suicidal behavior (presence or absence of actual, interrupted, aborted, or preparatory behavior recorded separately); and potential lethality (medical damage rated 0-5, potential lethality rated 0-2). At baseline, this is measured by the baseline version. At each visit following this, this will be recorded on the since last visit. Higher scores indicate more severe suicidality.

    Time frame: 22 weeks

  4. Changes in Positive and Negative Mood States

    Mood states before/after ketamine sessions assessed by PANAS (Positive and Negative Affect Schedule). This will be measured at integration session 1 (week 2), 2 (week 4) and 3 (week 6). Used to measure an individual's emotional state, assessing two dimensions: Positive Affect (PA; captures feelings like enthusiasm and alertness), and Negative Affect (NA; measures distress and negative emotions like anger and anxiety).

    Time frame: Week 2 (integration session 1), Week 4 (integration session 2), Week 6 (optional - at ketamine dose 3), Week 6 (integration session 3 and end of treatment)

Other outcomes

  1. Changes in Depression

    Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.

    Time frame: 22 weeks

  2. Changes in Anxiety

    Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.

    Time frame: 22 weeks

  3. Changes in Stress

    Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.

    Time frame: 22 weeks

  4. Change in Alcohol dependence severity

    Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.

    Time frame: 22 weeks

  5. Sleep Quality

    As measured by the PSQI (Pittsburgh Sleep Quality Index). This Index has a minimum score of 0 and a maximum score of 21. The higher the score indicates worse sleep quality.

    Time frame: 22 weeks

  6. Executive function, cognitive flexibility and task switching

    To assess whether ketamine treatment improves executive functioning, specifically cognitive flexibility and task-switching ability, as measured by the Number-Letter Task (NLT). Key outcome measures include reaction time, accuracy, and switch cost (the performance difference between switch and repeat trials). Lower switch costs and faster, more accurate responses indicate improved executive control.

    Time frame: 22 weeks

  7. Executive functioning and cognitive flexibility

    To assess whether ketamine treatment improves executive functioning and set-shifting, the Wisconsin Card Sorting Test (WCST) will be used. Participants are required to match stimulus cards based on varying classification principles (e.g., color, shape, number), which change without warning. Key outcome measures include the number of categories completed, total errors, perseverative responses, and perseverative errors. Higher performance is indicated by more categories completed and fewer perseverative errors, reflecting improved cognitive flexibility and executive control.

    Time frame: 22 weeks

  8. Changes in Alcohol Urge

    To assess short term alcohol urge the Alcohol Urge Questionnaire (AUQ) will be used. This is a brief 8-item self-report questionnaire that evaluates acute alcohol craving as a single factor (unidimensional). Each item is rated on a Likert scale of 7 points, with higher scores indicating stronger urges to consume alcohol. Two of the questions are reversed scored.

    Time frame: 22 weeks

  9. Psychological inflexibility

    As measured by the 7-item self-report Acceptance and Action Questionnaire, version 2 (AAQ-II). The items are rated on a 7-point Likert scale from 1 ("Never true") to 7 ("Always true"). Higher total scores are indicative of greater psychological inflexibility, while lower scores suggest more psychological flexibility. Scores between 24 and 28 are often used as a potential clinical cutoff indicating psychological distress.

    Time frame: 22 weeks

  10. Severity of pain and impact on functioning

    Measured by The Brief Pain Inventory (BPI). Patients rate their current symptons, average experiences of pain and minimum and maximum intensities of symptoms on scales between 0 to 10. A total pain severity score can be found by averaging these individual items. Higher scores indicate greater severity and more interference. A score relating to impact on daily life can be calculated by averaging scores on each of the seven items, which also use scales from 0 to 10. Takes five minutes or less.

    Time frame: 22 weeks

  11. Withdrawal Status

    To determine changes in the severity of alcohol withdrawal symptoms the Revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar) will be used. This 10-item scale evaluates common withdrawal symptoms including nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache and orientation. Each item is rated on a scale from 0 to 7 (except orientation, which is rated 0-4), with a total score ranging from 0 to 67. Higher scores indicate more severe withdrawal symptoms.

    Time frame: At screening and prior to dosing (22 weeks).

  12. Drinking Diary

    Daily texts will be sent out to participants querying the amount of alcohol they have consumed. Participant responses to this will be recorded. This will be managed through SEMA software.

    Time frame: 22 weeks

  13. Changes in Quality of Life

    To assess whether treatment can improve quality of life as measured by the World Health Organization Quality of Life (WHOQOL-BREF). This 26-item questionnaire evaluates four domains of quality of life: physical health, psychological health, social relationships, and environment. Each item is rated on a 5-point Likert scale, and domain scores are transformed to a 0-100 scale. Higher scores indicate a better quality of life.

    Time frame: 22 weeks

  14. Treatment Satisfaction as measured by the CSQ-8 (client satisfaction questionnaire).

    This instrument measures clients satisfaction with treatment. Total scores range from 8 to 32, with the higher number indicating greater satisfaction.

    Time frame: Week 1 (baseline) and week 10

  15. Measurement of Drug Effect as measured by the PIQ-23

    To assess whether treatment enhances acute psychologically insightful experiences we will use the Psychological Insight Questionnaire (PIQ-23). This 23-item self-report consists of two subscales: (a) Avoidance and Maladaptive Patterns Insights and (b) Goals and Adaptive Patterns Insights. The tool evaluates an individual's awareness and understanding of their own psychological processes, including recognition of patterns in thoughts, emotions, and behaviors. Each item is rated on a 5-point Likert scale, with higher scores indicating greater psychological insight.

    Time frame: PIQ will be completed on the day of an integration session at 2, 4 and 6 weeks.

  16. CBT Session rating scale

    As measured by the session rating scale (SRS). Following each CBT session, both the therapist and participant will complete a brief post-session rating. This scale measures; relationship, goals \& topics, approach or method and overall psychotherapy session. Higher scores on each of these indicate a more positive experience.

    Time frame: 22 weeks

  17. Alcohol craving

    As measured by the Penn Alcohol Craving Scale (PACS). 5-item self-report questionnaire that evaluates alcohol craving over the past week. Measures frequency, intensity, duration of craving, perceived control over drinking, and overall craving severity. Each item is rated on a 7-point Likert scale (0-6). Total scores range from 0 to 30, with higher scores indicating greater craving.

    Time frame: 22 weeks

  18. Cognitive function, specifically attention and executive control

    Assessed by the Stroop Task and Number-Letter Task at week 1 (baseline) and week 10.

    Time frame: Week 1 and week 10

  19. Punishment insensitivity

    To assess whether ketamine treatment influences instrumental contingency learning and sensitivity to punishment, this will be measured by the Planets and Pirates Task. Key outcome measures include instrumental responses (e.g., click rates on each planet) and Pavlovian responses (e.g., active avoidance or shield use). Improved performance is indicated by increased avoidance of punished choices and enhanced detection of action-outcome contingencies.

    Time frame: Prior to MRI scan

  20. Changes in Alcohol Craving

    To assess whether ketamine treatment reduces acute alcohol craving across multiple dimensions, this will be measured by the Alcohol Craving Questionnaire Short Form-Revised (ACQ-SF-R). This 12-item questionnaire captures four factors: compulsivity, expectancy, purposefulness, and emotionality. Each item is rated on a Likert scale (strongly disagree - strongly agree), with higher scores indicating greater craving intensity. Takes less than 5 minutes to complete.

    Time frame: Before and after MRI scans at week 2, 4 and 6

  21. To measure changes in global cognitive functioning

    Global cognitive functioning assessed by the Montreal Cognitive Assessment (MoCA). The MoCA is a 30-point screening tool designed to detect mild cognitive impairment and assess multiple cognitive domains, including attention, concentration, executive functions, memory, language, visuospatial skills, conceptual thinking, calculations, and orientation. Higher scores indicate better cognitive performance, with a maximum score of 30.

    Time frame: Measured at screening and enrolment (visit 1, week 0), in addition to at follow-up 1 (visit 11, week 10)

07

Study locations

1 site
  • Drug Health Services, Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
    • Kirsten Morley, PhD · ContactKirsten.morley@sydney.edu.au
    • Central Contact Line · Contact0459877108
    • Paul Haber, MD, RACP, FAChAM · Principal investigator
    • Kirsten Morley, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Apr 2027, 16 months later.

Of 22 phase 1/2 interventional studies under Alcoholism, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 25, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Apr 10, 2027
CompletionEst.
Dec 10, 2027
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247370
Lead sponsor
South West Sydney Local Health District
Collaborators
University of Sydney
Responsible party
Kirsten Morley BPsych MPH PhD (Professor, South West Sydney Local Health District) — Principal investigator
First posted
Nov 25, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Apr 10, 2027 (estimated)
Completion
Dec 10, 2027 (estimated)
Last update
Nov 25, 2025

Study contacts

Kirsten C Morley, PhD
Contact
Kirsten.morley@sydney.edu.au
+61295153636
Ellen Towers
Contact
ellen.towers@sydney.edu.au

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion